Loading…
Based on limited metadata, this FDA Warning Letter issued in February 2019 was directed at La Vita Compounding Pharmacy, LLC, a pharmaceutical compounding operation. While the specific violations are not detailed in the available metadata, the warning letter indicates regulatory concerns related to drug manufacturing or compounding practices. The letter falls under FDA's drug product oversight, though the issuing office information is not available in this record.